No Data
No Data
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating
Tourmaline Bio Showcases Promising Candidate in Updated Presentation
Piper Sandler Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $65
Tourmaline Bio (TRML) Receives a Buy From Piper Sandler
Tourmaline Bio to Present at Upcoming Investor Conferences
Analysts Offer Insights on Healthcare Companies: Tourmaline Bio (TRML), Amicus (FOLD) and Kura Oncology (KURA)
No Data
No Data